生物风投企业RudaCure携手兽药领军企业温治和温治宠物开发动物药品

RudaCure Inc. (CEO Yongho Kim), a 生物风投企业 specializing in 感觉障碍 diseases, has signed a comprehensive MOU for 兽用 药物开发, production, and sales with Onhil Co., Ltd. (CEOs Kim Do-hyung and Yoo Jeong-woo) and Onhil Pet Co., Ltd. (CEOs Ko Hyun-gyu and Ryu Tae-seong), companies specializing in 兽药 临床试验 and distribution.

Under this agreement, the three companies will initially co-develop treatments for 伴侣动物, including ear 炎症 treatments, 干眼 and 角膜损伤 treatments, and dermatological formulations.

RudaCure Inc., which holds 药物开发 know-how and 专利s, will be responsible for 药物开发, while Onhil Co., Ltd. and Onhil Pet Co., Ltd. will handle 兽用 临床试验, production, and sales.

RudaCure Inc. already has licensing experience with 干眼症治疗药s and 角膜损伤 treatments in 2021 and 2023, and is currently also developing a best-in-class powerful 非麻醉性镇痛药. The company is also actively conducting research on 银屑病 and 特应性皮炎, and has recently been selected for the 2023 K-Bio Health Regional Center Support Program announced by 仁川科技园, receiving support for prototype development, 专利s and certifications, and 临床试验. Additionally, the company has been selected for KOTRA's foreign 投资引进 support program and plans to actively pursue overseas 投资引进 activities.

Onhil Co., Ltd. is a 伴侣动物 healthcare platform company based on 兽用 medicine under the vision of "One health. One happiness." The company is already supplying "DuraHeart SR-3," the world's first 3-month long-acting heartworm vaccine developed with a domestic 专利, to animal hospitals. Going forward, the company plans to continue bringing good 兽用 medicine-based products to market and grow into a company that contributes more to 伴侣动物 health.

Through the MOU among three companies with strong technology and sales capabilities, it is expected that specialized 兽用 药物开发 in the expanding 伴侣动物 制药 market will contribute to a healthy and happy coexistence between 伴侣动物 and humans.